Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
551,552 Clinical progress and challenges At present, there are more and more clinical trials regarding mitochondria-targeted therapies, covering different disease directions, especially diseases related to mitochondrial dysfunction, such as cancers, motor muscle diseases, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and rare mitochondrial diseases
In epilepsy, upregulated P 2 Y 1 receptor signaling disrupts Ca 2+ dynamics and enhances glutamate release
While the GR inhibitor M 5 [38,39] had no effect on TGR, naphthazarin and its derivatives JD155 and JD159 [36] inhibited TGR, but not selectively
DSIP flux across the BMEC monolayers was also found to be bidirectional, insensitive to metabolic inhibitors, and not altered by high concentrations of tryptophan
123 MizunoS.NakamuraT
Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jrgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clment K, Dor J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T, Bork P, Wang J, Ehrlich SD, Pedersen O, MetaHIT consortium
US$ 29.71
US$ 23.59
US$ 20.33
US$ 23.65
US$ 25.22
US$ 25.40
